Rochester、MNにおける肺がんの臨床試験
Rochesterとその周辺地域（約30マイル以内）の拠点で、肺がんに関する20件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer
被験者募集中第2相
- Mayo Clinic in Rochester, Rochester
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
被験者募集中第3相
- Mayo Clinic - Rochester ( Site 0073), Rochester
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- Mayo Clinic, Rochester
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
被験者募集中第2/3相
- Mayo Clinic in Rochester, Minnesota, Rochester
Molecular Analysis of Suspected or High-Risk Lung Cancer to Drive Individualized Care
被験者募集中観察研究
- Mayo Clinic in Rochester, Rochester
A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer
被験者募集中健康なボランティア歓迎
- Mayo Clinic in Rochester, Rochester
Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung
被験者募集中第3相
- Mayo Clinic, Rochester
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
被験者募集中第3相
- Mayo Clinic in Rochester, Rochester
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
被験者募集中第3相
- Mayo Clinic in Rochester, Rochester
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
被験者募集中第1相
- Xencor Investigative Site, Rochester
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
被験者募集中観察研究
- Mayo Clinic in Rochester, Rochester
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
被験者募集中第1/2相
- Mayo Clinic Rochester, Rochester
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
被験者募集中
- Mayo Clinic, Rochester
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
被験者募集中第1/2相
- Mayo Clinic Cancer Center, Rochester
Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer
被験者募集中第2相
- Mayo Clinic in Rochester, Rochester
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
被験者募集中第1/2相
- Mayo Clinic Cancer Center, Rochester
Insomnia in Patients With Metastatic Lung Cancer
被験者募集中観察研究
- Mayo Clinic in Rochester, Rochester
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
被験者募集中観察研究健康なボランティア歓迎
- Mayo Clinic, Rochester
Thoracic Specimen Registry
被験者募集中観察研究
- Mayo Clinic in Rochester, Rochester
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
被験者募集中第1/2相
- Mayo Clinic, Rochester
他の都市における肺がんの試験
- Houston, TX78件の研究
- Boston, MA62件の研究
- New York City, NY60件の研究
- Los Angeles, CA45件の研究
- Washington, DC41件の研究
- Arlington, VA41件の研究
- Chicago, IL41件の研究
- Nashville, TN40件の研究
- Baltimore, MD40件の研究
- St. Louis, MO39件の研究
- Columbus, OH37件の研究
- Philadelphia, PA36件の研究
Rochesterにおける他の研究
- 乳がん42件の研究
- 非小細胞肺癌37件の研究
- 転移性癌31件の研究
- がん（全種類）30件の研究
- 大腸癌29件の研究
- 卵巣がん29件の研究
- 多発性骨髄腫24件の研究
- 前立腺がん22件の研究
- 心不全22件の研究
- 膵臓がん22件の研究
- 子宮内膜がん20件の研究
- 慢性リンパ性白血病19件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。